Why Is the Global AMD Drugs Market Accelerating—and What Should C-Level Executives Know?
The global Age-related Macular Degeneration (AMD) drugs market is undergoing a pivotal transformation. Valued at US$9.55 billion in 2023, it is forecasted to reach US$17.37 billion by 2029, expanding at a robust CAGR of 10.7%. This upward trajectory is not only driven by the rising prevalence of AMD but also by groundbreaking advancements in ophthalmology drugs, favorable reimbursement policies, and...